

Fourth Regional Congress of Medical Oncology - REKONIO 2023

7.– 9. September 2023, Austria Trend hotel Ljubljana

Organisers: Slovenian Medical Association- Section for Medical Oncology

Oncology Institute of Ljubljana
REKOG

Expert Committee: J. Ocvirk (president), T. Mesti, S. Borstnar, E. Matos, S. Plestina, B. Belev, D. Radosavljevic, A. Pasic

Organizing Committee: J. Ocvirk (president), T. Mesti, E. Matos, S. Borstnar

Poster Awards Committee: T. Mesti (president), B. Belev, D. Radosavljević, L. Popović, E. Matos

<https://rekogconference.com/>

FINAL PROGRAM

07th September 2023

9.30-11.00	<u>Registration</u>
11.00-13.30	<i>Genitourinary cancers: Moderated by Seruga, Belev</i> <i>Session supported by: Novartis</i>
11.00-11.20	How far have we come with immuno-oncology in GU cancers? Gnjudic
11.20-11.40	Beyond immunotherapy: new targets and new drugs in GU cancers: Belev
11.40-12.00	Management of oligometastatic and oligo-progressive disease in GU: Milasevic
12.00-12.20	Onco-nephrology: current concepts and future perspectives: Milanez
12.20-12.40	What does the future bring in the systemic treatment of GU cancers? Seruga
12.40-13.30	<i>Integrating supportive & palliative care & geriatrics with oncology - clinical cases: Round table</i>

Moderated by Ebert

Panellists: Ebert, Bosnjak, Zist, Cale

- **Supportive care**
- **Palliative care**
- **Geriatric oncology**

13.30 – 14.30 **Lunch break**

14.30 – 17.30 ***Clinical controversies in the breast cancer***

14.30- 16.00 **Early breast cancer** (Slovenian medical oncologists will present actual cases): *Moderated by Borstnar*

Session supported by: Novartis, Lilly

Panellists: Silovski, Popovic, Susnjar, Lekic, Ribnikar, Caks, Dobovisek, Pernek

- **How to decide to omit chemotherapy in early HR+/Her2-BC: gene signatures and other biomarkers:** Borštnar
- **Duration of endocrine therapy:** Ribnikar
- **Optimal treatment in early HER2 + BC:** Caks
- **Post Neoadjuvant therapy in TNBC:** Dobovisek
- **Adjuvant systemic therapy for patients with germline BRCA1/2 mutations:** Pernek

16.00-16.20 **Break**

16.20- 18.00 ***Advanced breast cancer*** (Slovenian medical oncologists will present actual cases): *Moderated by Borstnar*

Session supported by: AstraZeneca, Pfizer, Lilly

Panellists: Beslija, Dedic- Plavetic, Stamatovic, Bozovic- Spasojevic, Matos, Ovcaricek, Kovac, Demsar, Grašic Kuhar, Snoj Sarvari

- **The treatment beyond CDK4/6 in ABC:** Matos
- **Management of patients with metastases in CNS:** Ovcaricek
- **HER2-low ABC:** Kovac
- **Oligometastatic disease:** Demsar

- **Optimal management of a patient with ABC in a visceral crisis:** Grasic Kuhar
- **Optimal management of an older frail patient with ABC:** Snoj Sarvari

08th September 2023

9.00-9.30	Head and neck cancers: <i>Moderated by Kuhar Grasic</i> Discussion on experience with chemo-(immuno)therapy vs. mono-chemotherapy in relapsed/metastatic head and neck cancer Bisof, Kuhar Grasic
9.30 – 10.10	Round table – molecular markers in systemic therapy: <i>Moderated by Mesti</i> Panellists: Dedic- Plavetic, Mesti, Devjak Presentation of clinical cases: Leskovsek
10.10-10.30	Break
10.30-13.30	Lung cancers: <i>Moderated by Unk, Radosavljevic</i> Resectable NSCLC <i>session supported by: Roche, MSD, AstraZeneca</i>
10.30-10.50	Adjuvant treatment in NSCLC – to whom and when? Trivanovic
10.50-11.10	How to optimise perioperative treatment? Turnsek
11.10-11.30	The value of “early” end-points (MPR, pCR) in neoadjuvant trials: Devjak
11.30-12.00	Discussion Metastatic NSCLC <i>session supported by: Bristol Myers Squibb</i>
12.00-12.20	How far have we come with check-point inhibitors in metastatic NSCLC? Unk
12.20-12.40	How to manage patients after CPI resistance? Plestina
12.40-13.00	Druggable genomic alterations and available drugs in our region Radosavljevic

13.00-13.30	Discussion
13.30-14.30	Lunch break
14.30-16.40	<i>Gastrointestinal cancers: Moderated by Plestina, Ocvirk</i> <i>Upper GI cancers</i> <i>session supported by: Bristol Myers Squibb</i>
14.30-14.50	The future of the systemic treatment of the upper GIT cancers: Ocvirk <i>Pancreatic and hepatobiliary cancers</i> <i>session supported by: Roche</i>
14.50-15.10	Pancreatic cancer - The future of the systemic treatment: Nikolic
15.10-15.30	Hepatobiliary cancers – what a step forward: Plestina <i>Colorectal cancer</i> <i>session supported by: Servier</i>
15.30-15.50	The role of Gender differences in diagnosis and treatment of colorectal cancer: Pasic
15.50-16.40	Systemic treatment of the GIT cancers – to infinity and beyond: Moderated by Belev Panellists: Belev, Pasic, Rebersek, Mijalkovic, Nikolic Presentation of clinical cases: Erman
16.40-17.00	Break
17.00-17.30	<i>Poster session</i>
17.30-18.30	<i>Cooperation in the region</i>

09th September 2023

8.30-10.10	<i>Rare cancers: Moderated by Mesti</i>
8.30-8.50	Ocular melanoma: Simetic

- 8.50-9.10** **Cancer of unknown origin: Does primary origin still matter in the era of molecular profiling?** Matos
- 9.10-9.30** **GIST:** Belev
- 9.30-9.50** **Tailoring systemic therapy for medullary thyroid cancer:** Grasic Kuhar
- 9.50-10.10** **The clinical importance of molecular characteristics in brain cancers:** Mesti
- 10.10-10.50** ***Gynaecological cancers:*** *Moderated by Ravnik*
- 10.10-10.30** **The importance of BRCA/HRD status in tailoring maintenance treatment in 1st line ovarian cancer:** Stamatovic
- 10.30-10.50** **Immunotherapy in gynaecologic oncology – a new standard in metastatic endometrial and cervical cancer:** Ravnik
- 10.50-11.20** **Break**
- 11.20-13.00** ***Skin cancers:*** *Moderated by Kandolf Sekulovic, Hribernik*
- Non-melanoma skin cancers***
- 11.20-11.40** **Neoadjuvant/adjuvant immunotherapy in non-melanoma skin cancers:** Ocvirk
- Melanoma***
- session supported by: MSD, Novartis*
- 11.40-12.00** **Neoadjuvant and/or adjuvant immunotherapy in malignant melanoma – the best approach:** Jalovcic Suljevic
- 12.00-12.20** **Immune-related adverse events – the true meaning for skin cancer patients:** Hribernik
- 12.20- 13.00** **Systemic treatment of skin cancer and beyond:** *Moderated by Kandolf Sekulovic*
- Panellists:** Ocvirk, Herceg, Kandolf Sekulovic, Jalovcic Suljevic
- Presentation of clinical cases: Sever
- 13.00-13.15** ***Closing remarks***
- Ocvirk